Background: Positional indications for sublobar resection have been increasingly focused by clinical surgeons while the surgical strategies for cases involving inter-multisegmental veins (IMSVs) remain underreported. We want to further clarify the positional indications for sublobar resection in patients with clinical T1a–bN0 non-small cell lung cancer (NSCLC).

Methods: The clinical data of 686 patients from August 2021 to July 2022 were retrospectively analyzed. In the three-dimensional (3D) reconstruction images, we analyzed the prevalence and drainage patterns of typical IMSVs, specifically focusing on the lateral vein (Vl) in the upper lobes and the branches of the superior segmental vein (V⁶b) in the lower lobes. The potential association between lesion locations and surgical strategy was also analyzed.

Results: The prevalence of Vl, V⁶b2, and V⁶b3 was 58.5% (231/395), 98.3% (286/291), and 25.1% (73/291), respectively. Vl mainly drained into V²a+b (70/110, 63.6%) on the right and into V¹⁺²b+c (72/121, 59.5%) on the left. V⁶b2 and V⁶b3 mainly converged with other branches of the superior segmental vein. Limited resection was more feasible when the 2 cm simulated cutting margin of nodules did not involve IMSVs, or when lesions were located in the outer region. Multivariable logistic regression analyses identified four independent predictors for surgical procedure selection: (I) whether the 2 cm simulated cutting margin involves IMSVs; (II) diameter; (III) consolidation-to-tumour ratio (CTR); and (IV) depth ratio.

Conclusions: IMSVs exhibited high prevalences, with Vl showing diverse drainage patterns, while V⁶b2 and V⁶b3 displayed little variation. Depth ratio and the lesion’s relative location to the IMSVs were identified as longitudinal and transverse positional indications, respectively, for sublobar resection in patients with clinical T1a–bN0 NSCLC.

Keywords: Pulmonary nodule; three-dimensional reconstruction (3D reconstruction); inter-multisegmental vein (IMSV); sublobar resection

*Please mention the European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14) if using this research*

New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

*Please mention the European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14) if using this research*

Women who experience significant weight gain after the age of 20 and either have their first child after the age of 30 or don’t have children are almost three times more likely to develop breast cancer than those who give birth earlier and whose weight remains relatively stable, new research from the UK being presented at this year’s European Congress on Obesity (ECO 2025) has found.

UH Seidman Cancer Center has been approved for funding by the Patient-Centered Outcomes Research Institute (PCORI) to implement electronic monitoring of patient’s self-reported symptoms during cancer treatment.

Led by Co-Principal Investigators Dr. Peter Pronovost, MD, PhD, UH Chief Quality and Clinical Transformation Officer, and Veale Distinguished Chair in Leadership and Clinical transformation and  Melinda Hsu, MD, a medical oncologist at UH Seidman Cancer Center, this project aims to improve the quality of life and clinical outcomes for patients being treated for their cancer at UH Seidman Cancer Center by integrating electronic patient-reported outcome tools into EPIC, the electronic health record.  

Chemotherapy, as one of the primary ways to treat breast cancer, can put patients at high risk of side effects that can affect their adherence to treatment and quality of life. Alternative adjuvant therapy that can alleviate this effect can be beneficial for patients. A new study published in the journal Pharmacia showed that multi-strain probiotics can have impact on chemotherapy-related side effects through improved Karnofsky performance score and Blood Urea Nitrogen in breast cancer patients with chemotherapy.